Gandeeva Therapeutics’ Post

Cranmore Executive Search played a pivotal role in Horizon's rapid and successful expansion into the European market. "I highly recommend Cranmore," says Chris Serafino. "My contact, Chris Sannwald is a very effective partner and helps me not only find the right candidate and fit, but also is patient with me as my needs grow or change." Read the full case study below on how Cranmore's tailored approach to executive search empowered Horizon Therapeutics' European expansion and fuelled their remarkable success! 📈✨ #SuccessStories #ExecutiveSearch #EuropeanExpansion #HorizonTherapeutics

On today’s #BiotechHangout, hosts Daphne Zohar, Brad Loncar, Josh Schimmer, Tim Opler, and Chris Garabedian share perspectives on the general market with a look at private vs public M&A and impact on biotech sentiment, $ALNY positive ATTR drug data, $LYEL CAR-T cell therapy trial and patient death, and more data from $WVE, $NTLA, $SVRA & $VRNA, plus financings: Curie.bio ($380M Pro Rata Series A Fund), Formation ($372M Series D), $RXRX ($200M offering) and management perspectives: $DNA’s layoffs, $AMLX’s pivot w/ $35M GLP-1 buy, and more: https://lnkd.in/eFpaapDC

Aravive's Fight for Survival: Drastic Layoffs as Liquidation Looms Biotech firm Aravive confronts a critical phase after a disappointing Phase 3 trial for its ovarian cancer treatment. With limited funds, the company must secure a partner or funding in "several weeks" to continue operations, prompting a 70% workforce reduction. Pre-existing financial struggles were exacerbated by the trial failure, risking insolvency. Aravive seeks partners for their drug candidate, batiraxcept, requiring $100 million for Phase 3 and $50 million for midphase trials. Threatening their rights to batiraxcept, ongoing trial suspensions add complexity. As Aravive races against time, strategic partnerships are imperative; otherwise, liquidation or bankruptcy becomes likely, leaving suspense over its fate in the competitive biotech realm. #pharma #pharmaceutical #pharmtales #latestnews #pharmanews #pharmaceuticalindustry #biotech #ovariancancer #Aravive #pharmaceuticalcompanies #layoff https://lnkd.in/dhukEeMi

Thank you Seismic Therapeutic for your continued partnership! Internships for youth are #transformative because they focus on #aspiration. We ask our students to think beyond "what do you want to do when you grow up." We ask the more important questions like: - What work (skills) to you want to leverage in your career? Why? - What do you feel passionate about in the world? Why? - What impact do you want to drive for you and your community? Why? - What is your number ($), both income and wealth? Why? We actively encourage our interns to delay any #choices and expand their #mindset to aspire to anything and everything the working world has to offer. This makes our internship program #transformative because we do more than just build skills and talent pipelines: we ensure every young person can truly #aspire to a job that makes them feel fulfilled. This is what is missing in our current student-to-career system: a link between school and work that is focused on the learner, not just the pipeline. #labor is more than just #employers; it also comes down to #skills, #interest, #passion, and #fulfillment. Imagine if every young person could live and breath 3 different working environments in 3 different industries and build relationships with 3 different sets of organization staff, all before having to deal with the expectations of adulthood. ... now come join us and see how we make three years for youth turn into a lifetime of opportunity and wealth. #workforcedevelopment #education

BOOM "Although the news about Lykos seemed to spook investors and psychedelic medicine stocks including MindMed, Compass Pathways and Atai Life Sciences took a hit following the adcomm news, the situation doesn’t necessarily spell doom for the emerging drug class. Many of the adcomm’s concerns were specific to Lykos, and the larger challenge of functional unblinding wasn’t the panel’s only issue." https://lnkd.in/eFMe-b_F E. Matthew ("Whiz") Buckley Susan Buckley #investing #trading #stockmarket #stocks #stockstotrade #stockstobuy #options #optionstrading #optionstrader #finance #stocktowatch #stockmarketinvesting #financialtraining

Arovella Therapeutics ASX: ALA has released a recorded version of their recent roadshow presentation. Michael Baker takes listeners through the key aspects of the company. My favourite sections are: ✪ 19-minute mark: Discussion about Spontaneous Secondary Remission. There is no hashtag for this as it is rare to see in a cancer trial. ✪ 21-minute & 30-second mark: Discussion on the power of iNKT cells with #solidtumors. ✪ 24 minutes, 30 seconds mark strategy one to fight solid tumours working with Imugene Limited's onCARlytics virus. A plug for the video team, PRLX, for putting it together. #videopresentation #cancer #biotechnology

For those attending AcademyHealth #ARM24, come check out what Program on Regulation, Therapeutics, and Law (PORTAL) has been up to with some posters and presentations by me and incoming GIM fellow Chris Cai!

Discover the Wood family's journey with Triumph Therapeutics! 🌟 They share their experience about our evaluation process, describing it as 'impressive yet not overwhelming'. Dive into their story and see how we make therapy engaging and effective. #TriumphTherapy #FamilyTestimonial #EmpoweringJourneys

Spoke to Cody Shandraw earlier this week about the ongoing FDA priority review for Lykos Therapeutics MDMA-assisted therapy, and the chances of it passing. He firmly believes if approved by the FDA, with a slated time period of early August, that would we could see the following .. “I think you could see a market move unlike anything for an industry throughout public markets history” Does it seem bold? Well think about what’s happened this year. atai Life Sciences $50m investment into Beckley Psytech. Cybin Inc raising $150m with a number of strategic biotech investors. MindMed and the $175m they raised after their ground breaking phase 2 results. Reunion Neuroscience raising $103m. Not to mention, Lykos raised $100m back in January. If approved, you’re only going to see the valuation of this company increase dramatically. Check our latest podcast in the comment section. Doug Drysdale Robert Barrow Payton Nyquvest Cosmo Feilding Mellen Florian Brand Christian Angermayer Lars Christian Wilde E. Matthew ("Whiz") Buckley Elemer Piros Daniel Carcillo Joe Caltabiano Rob Crocker Graham Farrell Michael Boughner Tyler Beuerlein Michael Tan Rick Doblin Michael B. Galloro, CPA Barrington Miller #psychedelics #psychedelic #psychedelicstocks #mentalhealth #stocks